Patent ID: 7371761
Filing Date: 2008-05-13
Classification: A61K,A61P,C07D

Abstract:
1. A compound of Formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein; ring M, including P ring P, including P M P G is a group of Formula IIa or IIb: ring D, including the two atoms of Ring E to which it is attached, is a 5-6 membered ring consisting of: carbon atoms and 0-2 heteroatoms selected from the group consisting of N, O, and S(O) E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl, and is substituted with 1-2 R; alternatively, ring D is absent and ring E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, thienyl, and thiazolyl, and ring E is substituted with 1-2 R; alternatively, ring D is absent and ring E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, triazolyl, thienyl, and thiazolyl, and ring E is substituted with 1 R and with a 5-6 membered heterocycle consisting of: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O) R is selected from H, C alternatively, when 2 R groups are attached to adjacent atoms, they combine to form methylenedioxy or ethylenedioxy; A is a C B is Q is C═O; ring Q is a 6 membered monocyclic ring, wherein: 1-2 double bonds are present within the ring and the ring is substituted with 0-2 R X is absent; G R alternatively, when two R R R R R R alternatively, R R R R R alternatively, R R R R R R R (CR R R R (CR R R R R alternatively, R R n, at each occurrence, is selected from 0, 1, 2, and 3; p, at each occurrence, is selected from 0, 1, and 2; r, at each occurrence, is selected from 0, 1, 2, 3, 4, 5, and 6; r1, at each occurrence, is selected from 1, 2, 3, 4, 5, and 6; and t, at each occurrence, is selected from 0, 1, 2, and 3.